endTB-Q: "Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance"

Study Director
Lorenzo Guglielmetti, MD, PhD; Médecins Sans Frontières France; and Carole Mitnick, PhD; Harvard Medical School
Start Date
3 / 2020
Trial Phase
Phase III
Trial Status
Current Enrollment
169 (March 2022)
Target Enrollment

The endTB-Q clinical trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of a new, all-oral, shortened regimen for fluoroquinolone-resistant multidrug-resistant tuberculosis (MDR-TB). Experimental treatment duration is 6 to 9 months, defined for each participant according to disease extension at baseline and on-treatment response. endTB-Q is currently enrolling participants across six sites in four countries (India, Pakistan, Peru, Vietnam). Primary outcome results are expected for late 2024.

endTB-Q experimental regimen: Bdq-Cfz-Dlm-Lzd

For more information on this trial, visit the project website at